Nasdaq
$1.18▲ 4.42%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $39.7MShares out 33.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 3d agoAfter-hours26.10.22 05:15SCHEDULE 13D/AOwnership#●●●
Dogwood Therapeutics, Inc.
A Schedule 13D/A filing has been submitted for Dogwood Therapeutics, Inc. Sealbond Ltd has filed as a reporting person to update their beneficial ownership status in the company.…more
$1.18+4.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.10.19 21:458-KKey event
Dogwood Therapeutics, Inc.
Dogwood Therapeutics (DWTX) has secured a $5 million private placement from its largest shareholder, CK Life Sciences. The company will issue 4,098,360 shares of common stock at $1.22 per share, with proceeds intended to fund Phase 3 preparatory activities and extend the company's operational runway through March 2027.…more
$1.18+4.42%vs prev closeView filingShare - 8.13Pre-market26.08.13 21:508-KKey event
Dogwood Therapeutics, Inc.
Dogwood Therapeutics reported a net loss of $11.5 million, or $0.34 per share, for the second quarter of 2026. The company recognized a $6.7 million net non-cash impairment charge due to a decline in stock price and maintains $9.6 million in cash, providing an operational runway through the fourth quarter of 2026.…more
$1.18+4.42%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:35Bullish#●●●#●●●#●●●
Dogwood Therapeutics Announces $5M Private Placement
Dogwood Therapeutics has entered into a securities subscription agreement to raise $5 million from its largest shareholder, CK Life Sciences. The proceeds will be used to fund Phase 3 preparatory activities for its drug candidate, Halneuron, and support general operations.…more
$1.18+4.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoPre-market26.10.19 21:30
●●●●●●●● ●●●●● ●●●●●●
Dogwood Therapeutics has announced a $5 million private placement with its largest shareholder to fund Phase 3 preparatory activities. The proceeds are expected to extend the company's operational runway through March 2027.…more
$1.18+4.42%vs prev close - 10.6Pre-market26.10.06 21:45
●●●●●●●● ●●●●● ●●●●●●
Dogwood Therapeutics announced its participation in the 2026 Maxim Growth Summit to engage with institutional investors. The company is preparing to release topline data from its Phase 2b trial for its lead non-opioid analgesic candidate in November 2026.…more
$1.18+4.42%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report